Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology · 28.02.2025 · 31 (Suppl) · S94-S111
DOI: 10.3350/cmh.2024.0811 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2025. Verfasst von Huma Saeed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Western Ontario, London, ON, Canada. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Fatty Liver. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, University of Western Ontario, London, ON, Canada.
- MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.
- Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- SeLiver Group, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- Department of Microbiology & Immunology, Western University, London, ON, Canada.
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
- Instituto de Salud Carlos III
Zitieren
APA
Saeed, H., Díaz, L. A., Gil-Gómez, A., Burton, J., Bajaj, J. S., Romero-Gomez, M., Arrese, M., Arab, J. P., & Khan, M. Q. (2025). Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 31(Suppl), S94-S111. https://doi.org/10.3350/cmh.2024.0811
Vancouver
Saeed H, Díaz LA, Gil-Gómez A, Burton J, Bajaj JS, Romero-Gomez M, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2025;31(Suppl):S94-S111. doi:10.3350/cmh.2024.0811
BibTeX
@article{Saeed2025,
author = {Saeed, Huma and Díaz, Luis Antonio and Gil-Gómez, Antonio and Burton, Jeremy and Bajaj, Jasmohan S and Romero-Gomez, Manuel and Arrese, Marco and Arab, Juan Pablo and Khan, Mohammad Qasim},
title = {Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {Suppl},
pages = {S94--S111},
doi = {10.3350/cmh.2024.0811}
}
EUVIMED